@article{KunzmannNgyuenStahletal.2019,
  author    = {Kunzmann, S. and Ngyuen, T. and Stahl, A. and Walz, J. M. and Nentwich, M. M. and Speer, C. P. and Ruf, K.},
  title     = {Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti - a case report},
  series = {BMC Pediatrics},
  volume    = {19},
  journal   = {BMC Pediatrics},
  doi       = {10.1186/s12887-019-1732-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201024},
  pages     = {353},
  year      = {2019},
  abstract  = {Background Incontinentia Pigmenti is a rare disease affecting multiple organs. Fifty of patients show affection of the eye with retinopathy and possible amaurosis being the worst outcome. Treatment has commonly been panretinal laser coagulation but intravitreal application of bevacizumab as VEGF-inhibitor has shown to effectively suppress retinal neovascularization. Case presentation A six-week-old female infant with Incontinentia Pigmenti developed a foudroyant necrotizing enterocolitis shortly after intravitreal injection of bevazicumab due to a retinopathy with impending tractional detachment of the left eye. Since the onset of abdominal symptoms occurred immediately after the intravitreal application, a link between the two events seemed likely. Sequential analyses of the VEGF serum concentrations showed a massive suppression of endogenous VEGF with only a very slow recovery over weeks. Such a severe systemic adverse event has not been reported after intravitreal treatment with bevacizumab in an infant. Conclusion This case report shows a relevant systemic uptake of bevacizumab after intravitreal application as suppressed VEGF levels show. There seems to be a connection between suppressed VEGF levels and the onset of necrotizing enterocolitis. Therefore, treatment with bevacizumab should be carefully considered and further research is needed to assess this drug's safety profile.},
  language  = {en}
}